148 related articles for article (PubMed ID: 34090645)
21. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
[TBL] [Abstract][Full Text] [Related]
22. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer.
Weykamp F; König L; Seidensaal K; Forster T; Hoegen P; Akbaba S; Mende S; Welte SE; Deutsch TM; Schneeweiss A; Debus J; Hörner-Rieber J
Front Oncol; 2020; 10():987. PubMed ID: 32676455
[No Abstract] [Full Text] [Related]
23. Local treatment of oligometastatic disease: current role.
Winkelmann MT; Clasen S; Pereira PL; Hoffmann R
Br J Radiol; 2019 Aug; 92(1100):20180835. PubMed ID: 31124700
[TBL] [Abstract][Full Text] [Related]
24. Oligometastatic Colorectal Cancer Management: A Survey of the Italian College of Interventional Radiology.
Calandri M; Gazzera C; Giurazza F; Yevich S; Strazzarino GA; Brino J; Marra P; Contegiacomo A; Bargellini I; Cariati M; Fonio P; Veltri A
Cardiovasc Intervent Radiol; 2020 Oct; 43(10):1474-1483. PubMed ID: 32449016
[TBL] [Abstract][Full Text] [Related]
25. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
26. Patients with colorectal lung oligometastases (L-OMD) treated by dose adapted SABR at diagnosis of oligometastatic disease have better outcomes than patients previously treated for their metastatic disease.
Mihai A; Mu Y; Armstrong J; Dunne M; Beriwal S; Rock L; Thirion P; Heron DE; Bird BH; Westrup J; Murphy CG; Huq MS; McDermott R
J Radiosurg SBRT; 2017; 5(1):43-53. PubMed ID: 29296462
[TBL] [Abstract][Full Text] [Related]
27. Surgical management of oligometastatic disease in gastric cancer.
Jin P; Ji X; Tian Y
Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):638-645. PubMed ID: 32147440
[TBL] [Abstract][Full Text] [Related]
28. Management of Oligometastatic Disease in Advanced Non-Small Cell Lung Cancer.
West H
Clin Chest Med; 2020 Jun; 41(2):249-258. PubMed ID: 32402360
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
30. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
31. Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives.
Ottaiano A; Santorsola M; Circelli L; Trotta AM; Izzo F; Perri F; Cascella M; Sabbatino F; Granata V; Correra M; Tarotto L; Stilo S; Fiore F; Martucci N; Rocca A; Picone C; Muto P; Borzillo V; Belli A; Patrone R; Mercadante E; Tatangelo F; Ferrara G; Di Mauro A; Scognamiglio G; Berretta M; Capuozzo M; Lombardi A; Galon J; Gualillo O; Pace U; Delrio P; Savarese G; Scala S; Nasti G; Caraglia M
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980713
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study.
Mielgo-Rubio X; Garde-Noguera J; Juan O; Couñago F
World J Clin Oncol; 2020 Dec; 11(12):983-989. PubMed ID: 33437660
[TBL] [Abstract][Full Text] [Related]
33. Functional Magnetic Resonance Imaging and Oculomotor Dysfunction in Mild Traumatic Brain Injury.
Rockswold SB; Burton PC; Chang A; McNally N; Grant A; Rockswold GL; Low WC; Eberly LE; Yacoub E; Lenglet C
J Neurotrauma; 2019 Apr; 36(7):1099-1105. PubMed ID: 30014758
[TBL] [Abstract][Full Text] [Related]
34. A Prediction Model to Optimize Invasive Mediastinal Staging Procedures for Non-small Cell Lung Cancer in Patients With a Radiologically Normal Mediastinum: The Quebec Prediction Model.
Guinde J; Bourdages-Pageau E; Collin-Castonguay MM; Laflamme L; Lévesque-Laplante A; Marcoux S; Roy P; Ugalde PA; Lacasse Y; Fortin M
Chest; 2021 Dec; 160(6):2283-2292. PubMed ID: 34119514
[TBL] [Abstract][Full Text] [Related]
35. Imaging modalities in synchronous oligometastatic prostate cancer.
Futterer JJ; Surcel C; van den Bergh R; Borgmann H; Briganti A; Gandaglia G; Kretschmer A; Ost P; Sooriakumaran P; Tilki D; Valerio M; Ploussard G; De Visschere PJL; Tsaur I;
World J Urol; 2019 Dec; 37(12):2573-2583. PubMed ID: 30069582
[TBL] [Abstract][Full Text] [Related]
36. Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.
Joice GA; Rowe SP; Pienta KJ; Gorin MA
Curr Opin Urol; 2017 Nov; 27(6):533-541. PubMed ID: 28863016
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Significance of Oligometastatic Disease Classification by the ESTRO/EORTC of Cancer for Patients With Lung Cancer Treated With Definitive Radical Radiotherapy.
Chen HJ; Tu CY; Hsia TC; Fang HY; Chen CH; Chen SC; Li CH; Liao YM; Hsieh CY; Lein MY; Liang JA; Chien CR
Anticancer Res; 2020 Oct; 40(10):5895-5899. PubMed ID: 32988920
[TBL] [Abstract][Full Text] [Related]
38. Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study.
Zeng F; Lu T; Xie F; Chen L; Zhang L; Su Y; Yu Z; Xiao Y; Ao F; Li G; Chen Z; Gong X; Li J
Transl Oncol; 2021 Nov; 14(11):101187. PubMed ID: 34365221
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications.
Adamiak-Giera U; Jawień W; Pierzchlińska A; Białecka M; Kobierski JD; Janus T; Gawrońska-Szklarz B
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575471
[TBL] [Abstract][Full Text] [Related]
40. Oligometastatic Disease and Interventional Oncology: Rationale and Research Directions.
Murali N; Ludwig JM; Nezami N; Kim HS
Cancer J; 2020; 26(2):166-173. PubMed ID: 32205542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
